Document Detail

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
MedLine Citation:
PMID:  22252465     Owner:  NLM     Status:  MEDLINE    
Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines recommend alemtuzumab subcutaneous (SC) over IV. There is no report of alemtuzumab SC in MS. We report two patients with highly active relapsing MS who were treated with SC alemtuzumab, had significant improvement and tolerated SC alemtuzumab well without the typical infusion-associated adverse events. SC alemtuzumab in MS warrants further studies as this may enhance patient convenience and minimize infusion-associated adverse events.
Jai S Perumal; Farng Foo; Perry Cook; Omar Khan
Related Documents :
8335675 - The halo-ilizarov distraction cast for correction of cervical deformity. report of six ...
22398045 - Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and wi...
20466475 - Facial morphology changes after total maxillary setback osteotomy.
9294505 - Distraction osteogenesis for correction of transverse mandibular deficiency: a prelimin...
8371375 - Gunshot wounds to the male external genitalia.
21879275 - Screening for lynch syndrome in colorectal cancer: are we doing enough?
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-01-17
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  18     ISSN:  1477-0970     ISO Abbreviation:  Mult. Scler.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-18     Completed Date:  2012-11-27     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  1197-9     Citation Subset:  IM    
Department of Neurology, Weill Cornell Medical College, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / administration & dosage*,  adverse effects
Disability Evaluation
Immunologic Factors / administration & dosage*,  adverse effects
Infusions, Subcutaneous
Magnetic Resonance Imaging
Multiple Sclerosis, Relapsing-Remitting / diagnosis,  drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Immunologic Factors; 3A189DH42V/alemtuzumab
Comment In:
Expert Rev Clin Immunol. 2012 Jul;8(5):423-6   [PMID:  22882217 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The oncology of otology.
Next Document:  No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients.